FR2999431B1 - Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes - Google Patents

Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes

Info

Publication number
FR2999431B1
FR2999431B1 FR1262178A FR1262178A FR2999431B1 FR 2999431 B1 FR2999431 B1 FR 2999431B1 FR 1262178 A FR1262178 A FR 1262178A FR 1262178 A FR1262178 A FR 1262178A FR 2999431 B1 FR2999431 B1 FR 2999431B1
Authority
FR
France
Prior art keywords
inflammation
treatment
monoclonal antibodies
bacterial infections
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1262178A
Other languages
English (en)
Other versions
FR2999431A1 (fr
Inventor
Romeuf Christophe De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB Biotechnologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1262178A priority Critical patent/FR2999431B1/fr
Application filed by LFB Biotechnologies SAS filed Critical LFB Biotechnologies SAS
Priority to EP19159751.7A priority patent/EP3514175A1/fr
Priority to JP2015547130A priority patent/JP6461808B2/ja
Priority to CA2894225A priority patent/CA2894225A1/fr
Priority to US14/652,352 priority patent/US20160185847A1/en
Priority to EP13818329.8A priority patent/EP2931749B1/fr
Priority to PCT/FR2013/053120 priority patent/WO2014096672A1/fr
Publication of FR2999431A1 publication Critical patent/FR2999431A1/fr
Application granted granted Critical
Publication of FR2999431B1 publication Critical patent/FR2999431B1/fr
Priority to US16/436,537 priority patent/US20190375835A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
FR1262178A 2012-12-17 2012-12-17 Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes Expired - Fee Related FR2999431B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR1262178A FR2999431B1 (fr) 2012-12-17 2012-12-17 Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
JP2015547130A JP6461808B2 (ja) 2012-12-17 2013-12-17 炎症および細菌感染症処置におけるモノクローナル抗体の使用
CA2894225A CA2894225A1 (fr) 2012-12-17 2013-12-17 Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
US14/652,352 US20160185847A1 (en) 2012-12-17 2013-12-17 Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
EP19159751.7A EP3514175A1 (fr) 2012-12-17 2013-12-17 Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
EP13818329.8A EP2931749B1 (fr) 2012-12-17 2013-12-17 Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
PCT/FR2013/053120 WO2014096672A1 (fr) 2012-12-17 2013-12-17 Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
US16/436,537 US20190375835A1 (en) 2012-12-17 2019-06-10 Use of monoclonal antibodies for the treatment of inflammation and bacterial infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1262178A FR2999431B1 (fr) 2012-12-17 2012-12-17 Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes

Publications (2)

Publication Number Publication Date
FR2999431A1 FR2999431A1 (fr) 2014-06-20
FR2999431B1 true FR2999431B1 (fr) 2016-03-18

Family

ID=48468407

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1262178A Expired - Fee Related FR2999431B1 (fr) 2012-12-17 2012-12-17 Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes

Country Status (1)

Country Link
FR (1) FR2999431B1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
AU2010208125B2 (en) * 2009-01-29 2015-02-12 Medimmune, Llc Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding

Also Published As

Publication number Publication date
FR2999431A1 (fr) 2014-06-20

Similar Documents

Publication Publication Date Title
FR22C1048I2 (fr) Anticorps anti-cd3 et méthodes d'utilisation
FR24C1001I1 (fr) Anticorps anti-pd1 et leur utilisation en tant qu'agents thérapeutiques et de diagnostic
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
FR3012140B1 (fr) Unite et procede pour la purification de methacrylate de methyle brut
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
FR2929946B1 (fr) Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
FR3013184B1 (fr) Utilisation d'hydroxyapatite pour le traitement de l'esca
MA43361A (fr) Composition pour le soin et la protection de cultures
FR20C1044I2 (fr) Triazines pour le traitement des infections protozoïques
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA40512A (fr) Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
FR2999191B1 (fr) Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
FR2977798B1 (fr) Utilisation de composes oligosaccharidiques pour la prevention et le traitement des cicatrices pathologiques
MA48751A (fr) Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax
FR2992219B1 (fr) Composition pour le traitement de l'hypocalcemie chez les ruminants

Legal Events

Date Code Title Description
TP Transmission of property

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20141126

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20230808